Glenmark Pharmaceuticals

Branded Portfolio Expansion Will Drive Global Emerging Market Access

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Dec 24

Updated

02 Dec 25

Views

37

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

29.9%

7D

1.4%

Loading

1Y

29.9%

7D

1.4%

You can edit this narrative until Dec 3 7:10 PM. Then, changes will post as Updates.

Author's Valuation

₹2.11k6.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 02 Dec 25

Fair value Decreased 0.78%

GLENMARK: Recent Regulatory Progress And Product Launches Will Balance Near-Term Margins

Analysts have adjusted their fair value estimate for Glenmark Pharmaceuticals slightly downward from ₹2,128.58 to ₹2,112.00. This revision is due to marginally lower expectations for revenue growth and profit margins moving forward.

Shared on 18 Nov 25

Fair value Decreased 5.25%

GLENMARK: Improving Margins And Trial Expansion Will Drive Shares Higher

Glenmark Pharmaceuticals: Analyst Price Target Update Analysts have revised Glenmark Pharmaceuticals' fair value estimate downward from ₹2,246.45 to ₹2,128.58. This revision is due to slower projected revenue growth, which is partially offset by improved profit margins and a lower future price-to-earnings ratio.

Shared on 03 Sep 25

Fair value Increased 2.70%

The modest upward revision in Glenmark Pharmaceuticals' consensus price target to ₹2246 appears primarily driven by a slightly higher future P/E multiple, with revenue growth forecasts largely unchanged. What's in the News Glenmark announced the upcoming US launch of Micafungin for Injection, entering a $60.7 million annual market with a bioequivalent product to Astellas Pharma's Mycamine.

Shared on 24 Jul 25

Fair value Increased 6.13%

With Glenmark Pharmaceuticals' future P/E ratio edging up from 31.26x to 32.17x while net profit margin remains stable, the consensus analyst price target is unchanged at ₹2061. What's in the News Glenmark launched TEVIMBRA® (tislelizumab), an anti-PD-1 monoclonal antibody for NSCLC and ESCC, marking its entry into immune-oncology in India.

Shared on 01 May 25

Fair value Increased 31%

Shared on 23 Apr 25

Fair value Increased 0.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.091%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.75%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 6.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 0.98%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 1.74%

AnalystConsensusTarget Fair Value

₹2.11k

6.9% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

4.91%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹33.10b

Earnings '28

x

25.80x

PE Ratio '28

=

₹853.86b

Market Cap '28

₹853.86b

Market Cap '28

/

282.09m

No. shares '28

=

₹3.03k

Share Price '28

₹3.03k Share Price '28

Discounted to 2025 @ 12.76% p.a.

=

₹2.11k

Fair Value '25